EMA Authorised: Benlysta (belimumab) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

EMA authorised Benlysta (belimumab) for systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• BENLYSTA (belimumab)

Snippet

Status: Authorised. Therapeutic area: Lupus Erythematosus, Systemic. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 25/09/2025